{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:22:44Z","timestamp":1792293764596,"version":"4.4.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T00:00:00Z","timestamp":1576713600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005624","name":"PATH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005624","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.vaccine.2019.12.017","type":"journal-article","created":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T18:08:50Z","timestamp":1576865330000},"page":"1302-1314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":109,"title":["Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2353-2352","authenticated-orcid":false,"given":"Hilary S.","family":"Whitworth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5604-7647","authenticated-orcid":false,"given":"Katherine E.","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4174-7349","authenticated-orcid":false,"given":"Natasha","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2801-379X","authenticated-orcid":false,"given":"Sandra","family":"Mounier-Jack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gladys","family":"Mbwanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6073-2591","authenticated-orcid":false,"given":"Aim\u00e9e R.","family":"Kreimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0124-4050","authenticated-orcid":false,"given":"Partha","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Drolet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Brisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Watson-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.12.017_b0005","unstructured":"Ghebreyesus TA, Director General. World Health Organisation. Cervical Cancer: An NCD we can overcome; 2018. Available at: https:\/\/www.who.int\/reproductivehealth\/DG_Call-to-Action.pdf. Last accessed: 28 January 2019."},{"key":"10.1016\/j.vaccine.2019.12.017_b0010","unstructured":"World Health Organization IAfRoC. GLOBOCAN 2018. Cervix Uteri. 2018. Available from: http:\/\/gco.iarc.fr\/today\/fact-sheets-cancers. Last accessed: 28 January 2019."},{"issue":"5","key":"10.1016\/j.vaccine.2019.12.017_b0015","doi-asserted-by":"crossref","first-page":"F12","DOI":"10.1016\/j.vaccine.2012.07.055","article-title":"Global burden of human papillomavirus and related diseases","volume":"30","author":"Forman","year":"2012","journal-title":"Vaccine."},{"issue":"1","key":"10.1016\/j.vaccine.2019.12.017_b0020","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ijgo.12182","article-title":"Ending cervical cancer: A call to action","volume":"138","author":"Aranda","year":"2017","journal-title":"Int J Gynaecol Ocstet"},{"issue":"5","key":"10.1016\/j.vaccine.2019.12.017_b0025","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1016\/j.vaccine.2012.04.108","article-title":"A review of clinical trials of human papillomavirus prophylactic vaccines","volume":"30","author":"Schiller","year":"2012","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2019.12.017_b0030","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1017\/S0950268817000747","article-title":"Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence","volume":"145","author":"Signorelli","year":"2017","journal-title":"Epidemiol Infect"},{"issue":"8","key":"10.1016\/j.vaccine.2019.12.017_b0035","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.12.017_b0040","unstructured":"WHO. Human papillomavirus vaccines: WHO position paper, October 2014. Weekly Epidemiological Record. 2014;89(43):465\u201392."},{"issue":"1","key":"10.1016\/j.vaccine.2019.12.017_b0045","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S2468-2667(16)30001-9","article-title":"Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models","volume":"1","author":"Brisson","year":"2016","journal-title":"Lancet Public Health."},{"issue":"1","key":"10.1016\/j.vaccine.2019.12.017_b0050","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/S2468-2667(18)30183-X","article-title":"The projected timeframe until cervical cancer elimination in Australia: a modelling study","volume":"4","author":"Hall","year":"2019","journal-title":"Lancet Public Health"},{"issue":"3","key":"10.1016\/j.vaccine.2019.12.017_b0055","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S1470-2045(18)30836-2","article-title":"Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020\u201399: a modelling study","volume":"20","author":"Simms","year":"2019","journal-title":"Lancet Oncol"},{"issue":"32","key":"10.1016\/j.vaccine.2019.12.017_b0060","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1016\/j.vaccine.2018.02.003","article-title":"Status of HPV vaccine introduction and barriers to country uptake","volume":"36","author":"Gallagher","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.017_b0065","unstructured":"PATH. Global HPV vaccine introduction overview. November 2019. Available at: https:\/\/www.path.org\/resources\/global-hpv-vaccine-introduction-overview\/Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO."},{"issue":"39","key":"10.1016\/j.vaccine.2019.12.017_b0070","doi-asserted-by":"crossref","first-page":"5042","DOI":"10.1016\/j.vaccine.2015.07.102","article-title":"Reduced dose human papillomavirus vaccination: An update of the current state-of-the-art","volume":"33","author":"Toh","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.017_b0075","unstructured":"Single-Dose HPV vaccine evaluation consortium. A general summary of current published evidence for single-dose HPV vaccination. 2018. Available at: http:\/\/www.rho.org\/files\/SingleDoseHPV_GeneralSummary_Sept2018.pdf. Last accessed: 28 January 2019."},{"issue":"32","key":"10.1016\/j.vaccine.2019.12.017_b0080","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1016\/j.vaccine.2018.02.076","article-title":"HPV single-dose vaccination: Impact potential, evidence base and further evaluation","volume":"36","author":"Stanley","year":"2018","journal-title":"Vaccine"},{"issue":"32","key":"10.1016\/j.vaccine.2019.12.017_b0085","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1016\/j.vaccine.2018.01.057","article-title":"Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs","volume":"36","author":"Markowitz","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.017_b0090","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cct.2018.02.010","article-title":"Design and statistical considerations for studies evaluating the efficacy of a single dose of the human papillomavirus (HPV) vaccine","volume":"68","author":"Sampson","year":"2018","journal-title":"Contemp Clin Trials"},{"issue":"7","key":"10.1016\/j.vaccine.2019.12.017_b0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2019.12.017_b0100","unstructured":"Deeks JJ, Higgins JP. Statistical algorithms in review manager 5. Statistical Methods Group of The Cochrane Collaboration; 2010. p. 1\u201311."},{"issue":"1","key":"10.1016\/j.vaccine.2019.12.017_b0105","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1158\/1940-6207.CAPR-15-0373","article-title":"Correction: Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the costa rica vaccine trial","volume":"9","author":"Safaeian","year":"2016","journal-title":"Cancer Prev Res (Phila)."},{"issue":"11","key":"10.1016\/j.vaccine.2019.12.017_b0110","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/1940-6207.CAPR-13-0203","article-title":"Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica vaccine trial","volume":"6","author":"Safaeian","year":"2013","journal-title":"Cancer Prev Res (Phila)"},{"issue":"32","key":"10.1016\/j.vaccine.2019.12.017_b0115","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1016\/j.vaccine.2017.12.078","article-title":"Evidence for single-dose protection by the bivalent HPV vaccine-Review of the Costa Rica HPV vaccine trial and future research studies","volume":"36","author":"Kreimer","year":"2018","journal-title":"Vaccine"},{"issue":"19","key":"10.1016\/j.vaccine.2019.12.017_b0120","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/jnci\/djr319","article-title":"Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16\/18 vaccine","volume":"103","author":"Kreimer","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.vaccine.2019.12.017_b0125","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1470-2045(15)00047-9","article-title":"Efficacy of fewer than three doses of an HPV-16\/18 AS04 adjuvanted vaccine: combined analysis of data from the Costa Rica vaccine trial and the PATRICIA trial","volume":"16","author":"Kreimer","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.vaccine.2019.12.017_b0130","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx158","article-title":"Durability of protection afforded by fewer doses of the HPV16\/18 vaccine: The CVT trial","volume":"110","author":"Safaeian","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.vaccine.2019.12.017_b0135","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1470-2045(15)00414-3","article-title":"Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study","volume":"17","author":"Sankaranarayanan","year":"2016","journal-title":"Lancet Oncol"},{"issue":"32","key":"10.1016\/j.vaccine.2019.12.017_b0140","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1016\/j.vaccine.2018.02.087","article-title":"Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study","volume":"36","author":"Sankaranarayanan","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.017_b0145","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ebiom.2016.06.042","article-title":"A single human papillomavirus vaccine dose improves B cell memory in previously infected subjects","volume":"10","author":"Scherer","year":"2016","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.vaccine.2019.12.017_b0150","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1080\/21645515.2016.1146429","article-title":"Less than 3 doses of the HPV vaccine \u2013 Review of efficacy against virological and disease endpoints","volume":"12","author":"Basu","year":"2016","journal-title":"Hum Vacc Immunother"},{"issue":"37","key":"10.1016\/j.vaccine.2019.12.017_b0155","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1016\/j.vaccine.2008.07.002","article-title":"Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica","volume":"26","author":"Herrero","year":"2008","journal-title":"Vaccine"},{"issue":"9686","key":"10.1016\/j.vaccine.2019.12.017_b0160","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.vaccine.2019.12.017_b0165","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/bjc.2016.97","article-title":"Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis","volume":"114","author":"Cuschieri","year":"2016","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.vaccine.2019.12.017_b0170","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1038\/bjc.2014.198","article-title":"Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16\/18 and closely related HPV types","volume":"110","author":"Kavanagh","year":"2014","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.vaccine.2019.12.017_b0175","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/infdis\/jiv753","article-title":"Natural acquired immunity against subsequent genital human papillomavirus infection: A systematic review and meta-analysis","volume":"213","author":"Beachler","year":"2016","journal-title":"J Infect Dis"},{"issue":"47","key":"10.1016\/j.vaccine.2019.12.017_b0180","doi-asserted-by":"crossref","first-page":"6303","DOI":"10.1016\/j.vaccine.2014.08.071","article-title":"Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda","volume":"32","author":"LaMontagne","year":"2014","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2019.12.017_b0185","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/cid\/ciw865","article-title":"Sustained antibody responses 6 years following 1, 2, or 3 doses of quadrivalent human papillomavirus (HPV) vaccine in adolescent fijian girls, and subsequent responses to a single dose of bivalent HPV vaccine: a prospective cohort study","volume":"64","author":"Toh","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2019.12.017_b0190","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/21645515.2018.1522469","article-title":"Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3\u20138 years later - an exploratory study","volume":"15","author":"Gilca","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"32","key":"10.1016\/j.vaccine.2019.12.017_b0195","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1016\/j.vaccine.2017.11.089","article-title":"Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development","volume":"36","author":"Pinto","year":"2018","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19316597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19316597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:39:59Z","timestamp":1759401599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19316597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0264410X19316597"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.12.017","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}